Substitution behaviour of novel dinuclear Pt(II) complexes with bio-relevant nucleophiles

Heterodinuclear Ru-Pt Complexes Bridged with 2,3-Bis(pyridyl)pyrazinyl Ligands: Studies on Kinetics, Deoxyribonucleic Acid/Bovine Serum Albumin Binding and Cleavage, In Vitro Cytotoxicity, and In Vivo Toxicity on Zebrafish Embryo Activities

Di- and poly-homo/heteronuclear complexes have great potential as anticancer drugs. Here, we report their reactivity, deoxyribonucleic acid (DNA)/bovine serum albumin (BSA) binding and cleavage interactions, in vitro cytotoxicity, and in vivo zebrafish embryo toxicity of [(phen)₂Ru(μ-L)PtCl₂]²⁺ (phen = 1,10-phenanthroline and L = 2,3-bis(2-pyridyl)pyrazine, bpp, C₁ ; 2,3-bis(2-pyridyl)quinoxaline, bpq, C_2ial ; 2,3-bis(2-pyridyl)benzo[g]quinoxaline, bbq, C₃ ) anticancer prodrugs. The substitution reactivity increases from C₁ to C₃ owing to an increase in the π-conjugation on the bridging chelate which facilitates π-back bonding. As a result, the electrophilicity index on the C₃ complex increases than that on the complex C₂ followed by C₁ which leads to higher rates of substitution and thus the reactivity order follows C₁ < C₂ < C₃ . The coordination of Ru at one end of each of the complexes enhances water solubility. Moreover, the charge addition of the two metal ions increases their reactivity toward substitution in addition to ensuring electrostatic interactions at target sites such as the DNA/BSA. Spectroscopic (UV-vis absorption and fluorescence quenching) titration and viscosity measurement results of the interactions of C_1/2/3 with CT-DNA established the formation of stable, nonconvent C_1/2/3 -DNA adducts with DNA most likely via the intercalative binding mode. Furthermore, studies with BSA showed a good binding affinity of these complexes owing to hydrophobic interactions with the coordinated ligands. The interactions of these complexes with DNA/BSA are in line with the reactivity trend, and all these experimental findings were further supported by molecular docking analysis. In vitro MTT cytotoxic activities on human breast cancer cell line MCF-7 revealed that all the complexes have high cytotoxicity activity (IC₅₀ > 9 μM); furthermore, the selectivity index and SI values were higher (>3). Complex C₃ showed the highest cytotoxicity with IC₅₀ = 3.1 μM and SI value (5.55) against MCF7 cell lines and these values were comparable to those of the cisplatin (IC₅₀ and SI values are 5.0 μM and 4.02, respectively). In vivo toxicological assessments on zebrafish embryos revealed that all the Ru-Pt complexes (C_I/2/3 ) have poor embryo acute toxic effects over 96 h postfertilization, hpf with LC₅₀ > 65.2 μM. The complex C₃ has shown the lowest embryo toxicity (LC₅₀ = 148.8 μM), which is comparable to that of commercial cisplatin (LC₅₀ = 181.1 μM). Based on the cytotoxicity results, complexes C₂ and C₃ could be considered for further development as chemotherapeutic agents against MCF breast cancer cells.

A kinetic and mechanistic study of analogous bifunctional dialkylamine platinum(ii) complexes

A comparative substitution behaviour of isomeric cis/trans-platinum(ii) complexes.

Seven membered chelate Pt(ii) complexes with 2,3-di(2-pyridyl)quinoxaline ligands: studies of substitution kinetics by sulfur donor nucleophiles, interactions with CT-DNA, BSA and in vitro cytotoxicity activities

Dichloro platinum(ii) complexes coordinated with 2,3-di(2-pyridyl)quinoxaline ligands which form seven-membered chelates namely, bpqPtCl2, dmbpqPtCl2 and bbqPtCl2 (where bpq, dmbpq and bbq are 2,3-di(2-pyridyl)quinoxaline, 6,7-dimethyl-2,3-di(2-pyridyl)quinoxaline and 2,3-bis(2'pyriyl)benzo[g]quinoxaline, respectively) were synthesized, characterised and their respective hydrated product complexes namely, bpqPt(OH2)2 2+, dmbpqPt(OH2)2 2+ and bbqPt(OH2)2 2+ were prepared by chloride metathesis. The substitution kinetics of the aquated cations by thiourea nucleophiles indicated that the two aqua ligands are substituted simultaneously according to the rate law: k obs = k 2[Nu]. This is followed by a forced dechelation of the ligands from the Pt (II) to form Pt(Nu)4 2+ species. The dechelation step is considerably slow to be monitored reliably. The rate of substitution is marginally enhanced by introducing two methyl groups and by extending the π-conjugation on the bpq core ligand. The reactivity order increased as bpqPt(OH2)2 2+ < dmbpqPt(OH2)2 2+ < bbqPt(OH2)2 2+. Reactivity trends were well supported by theoretical computed DFT electronic descriptors. The interactions of the Pt(ii) complexes with CT-DNA and BSA were also examined spectroscopically in tris buffers at pH 7.2. Spectroscopic and viscosity measurements suggested strong associative interactions between the Pt(ii) complexes and CT-DNA, most likely through groove binding. In silico theoretical binding studies showed energetically stable poses through associative non-covalent interactions. In vitro MTT cytotoxicity IC50 values of the Pt(ii) complexes on human liver carcinoma cells (HepG2) cancer cell lines revealed bbqPtCl2 as the least active. The fluorescence staining assays revealed the morphological changes suggested early apoptotic induction as well as non-specific necrosis.

New monofunctional platinum(II) and palladium(II) complexes: Studies of the nucleophilic substitution reactions, DNA/BSA interaction, and cytotoxic activity

Four new complexes [Pd(H₂L^tBu)Cl]Cl (Pd1), [Pt(H₂L^tBu)Cl]Cl (Pt1), [Pd(Me₂L^tBu)Cl]Cl (Pd2) and [Pt(Me₂L^tBu)Cl]Cl (Pt2) (where H₂L^tBu = 2,6-bis(5-(tert-butyl)-1H-pyrazol-3-yl)pyridine and Me₂L^tBu = 2,6-bis(5-(tert-butyl)-1-methyl-1H-pyrazol-3-yl)pyridine) were synthesized and characterized by elemental microanalysis, IR, ¹H NMR and ESI-MS methods. The reactivity of complexes towards thiourea (Tu), l-methionine (l-Met), l-cysteine (l-Cys) and guanosine-5'-monophosphate (5'-GMP) was investigated. The obtained order was established as follows: Tu > l-Cys > l-Met > 5'-GMP. Complexes Pd1 and Pt1, that contain H₂L^tBu as chelator, showed higher reactivity towards biomolecules than those with Me₂L^tBu. The interaction of complexes with calf thymus DNA (CT-DNA) and bovine serum albumin (BSA) was studied by UV-Vis and fluorescence spectroscopy. The results have shown that complexes can bind to DNA exhibiting high binding constants (K_b = 10⁴ M^-1). Obtained results during the examination of competitive reaction with ethidium bromide (EB) showed that complexes can replace EB-bound DNA. High values of binding constants indicate good binding affinity of complexes towards BSA. We evaluated the stability differences between complexes based on terpy as well as H₂L^tBu/Me₂L^tBu by DFT calculations (B3LYP(CPCM)/LANL2DZp), showing that both tridentate ligand systems lead to complexes of similar stability. The results of biological testing showed that all complexes exert moderate to high selective cytotoxicity, inducing apoptosis and autophagy in HeLa and PANC-1 tumor cell lines. Pd1 exhibited the strongest cytotoxic effect. Finally, cell cycle analysis showed that in HeLa cells Pd1, Pd2 and Pt1 induced accumulation of cells in S phase, whereas in PANC-1 cells Pd2 and Pt1 induced G2/M cycle arrest and Pd1 induced G0/G1 arrest.

In vitro and in vivo anti-tumor effects of selected platinum(IV) and dinuclear platinum(II) complexes against lung cancer cells

In the present study, cytotoxic effects of cisplatin, the most usually used chemotherapeutic agent, were compared with new designed platinum(IV) ([PtCl₄(en)] (en = ethylenediamine) and [PtCl₄(dach)]) (dach = (±)-trans-1,2-diaminocyclohexane) and platinum(II) complexes ([{trans-Pt(NH₃)₂Cl}₂(μ-pyrazine)](ClO₄)₂ (Pt1), [{trans-Pt(NH₃)₂Cl}₂(μ-4,4'-bipyridyl)](ClO₄)₂DMF(Pt2),[{trans-Pt(NH₃)₂Cl}₂(μ-1,2-bis(4pyridyl)ethane)](ClO₄)₂ (Pt3)), in vitro and in vivo against human and murine lung cancer cells, to determine anti-tumor potential of newly synthesized platinum-based drugs in the therapy of lung cancer. Results obtained by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], Lactate dehydrogenase and Annexin V/Propidium Iodide assays showed that, among all tested complexes, [PtCl₄(en)] had the highest cytotoxicity against human and murine lung carcinoma cells in vitro. [PtCl₄(en)] showed significantly higher cytotoxicity then cisplatin in all tested concentrations, mainly by inducing apoptosis in lung cancer cells. [PtCl₄(en)] was well tolerated in vivo. Clinical signs of [PtCl₄(en)]-induced toxicity, such as changes in food, water consumption or body weight, nephrotoxicity or hepatotoxicity was not observed in [PtCl₄(en)]-treated mice. [PtCl₄(en)] managed to increase presence of CD45+ leukocytes, including F4/80+ macrophages, CD11c+ dendritic cells, CD4+ helper and CD8+ cytotoxic T cells (CTLs) in the lungs, cytotoxic NK, NKT and CTLs in the spleens of tumor bearing mice, resulting with reduction of metastatic lesions in the lungs, indicating its potential to stimulate anti-tumor immune response in vivo. Due to its anti-tumor cytotoxicity, biocompatibility, and potential for stimulation of anti-tumor immune response, [PtCl₄(en)] may be a good candidate for further testing in the field of medicinal chemistry.

New bimetallic palladium(ii) and platinum(ii) complexes: studies of the nucleophilic substitution reactions, interactions with CT-DNA, bovine serum albumin and cytotoxic activity

Nucleophilic substitution reactions, interactions with CT-DNA, bovine serum albumin and cytotoxic activity of new bimetallic Pt(ii) and Pd(ii) complexes.

Platinum(ii) complexes with hybrid amine-imidazolin-2-imine ligands and their reactivity toward bio-molecules

Two new Pt(ii) complexes with imidazolin-2-imines as ancillary ligands were synthesized and characterized and their reactivity toward bio-molecules was tested.

Palladium(ii) complexes with highly basic imidazolin-2-imines and their reactivity toward small bio-molecules

Pd(ii) complexes with chelating imidazolin-2-imine ligands were synthesized, and the pK_a values and reactivity of these complexes were investigated.